|
1
|
Horev L, Lees MM, Anteby I, et al:
Oculoectodermal syndrome with coarctation of the aorta and moyamoya
disease: expanding the phenotype to include vascular anomalies. Am
J Med Genet A. 155:577–581. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yamashita M, Oka K and Tanaka K:
Histopathology of the brain vascular network in moyamoya disease.
Stroke. 14:50–58. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takebayashi S, Matsuo K and Kaneko M:
Ultrastructural studies of cerebral arteries and collateral vessels
in moyamoya disease. Stroke. 15:728–732. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuroda S and Houkin K: Moyamoya disease:
current concepts and future perspectives. Lancet Neurol.
7:1056–1066. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vajkoczy P: Moyamoya disease:
collateralization is everything. Cerebrovasc Dis. 28:2582009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun Y, Jin K, Xie L, et al: VEGF-induced
neuroprotection, neurogenesis, and angiogenesis after focal
cerebral ischemia. J Clin Invest. 111:1843–1851. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang HT, Yan Z, Abraham JA and Terjung RL:
VEGF121- and bFGF-induced increase in collateral blood flow
requires normal nitric oxide production. Am J Physiol Heart Circ
Physiol. 280:H1097–H1104. 2001.PubMed/NCBI
|
|
8
|
Sakamoto S, Kiura Y, Yamasaki F, et al:
Expression of vascular endothelial growth factor in dura mater of
patients with moyamoya disease. Neurosurg Rev. 31:77–81. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rafat N, Beck GCh, Peña-Tapia PG,
Schmiedek P and Vajkoczy P: Increased levels of circulating
endothelial progenitor cells in patients with moyamoya disease.
Stroke. 40:432–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang HS, Kim JH, Phi JH, et al: Plasma
matrix metalloproteinases, cytokines and angiogenic factors in
moyamoya disease. J Neurol Neurosurg Psychiatry. 81:673–678. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park YS, Jeon YJ, Kim HS, et al: The role
of VEGF and KDR polymorphisms in moyamoya disease and collateral
revascularization. PLoS One. 7:e471582012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzuki J and Kodama N: Moyamoya disease -
a review. Stroke. 14:104–109. 1983. View Article : Google Scholar
|
|
13
|
Smith ER and Scott RM: Surgical management
of moyamoya syndrome. Skull Base. 15:15–26. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuroda S and Houkin K: Bypass surgery for
moyamoya disease: concept and essence of sugical techniques. Neurol
Med Chir (Tokyo). 52:287–294. 2012.PubMed/NCBI
|
|
15
|
Matsushima T, Fukui M, Kitamura K, et al:
Encephalo-duro-arterio-synangiosis in children with moyamoya
disease. Acta Neurochir (Wien). 104:96–102. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saito N and Imai H: Insights on the
revascularization mechanism for treatment of moyamoya disease based
on the histopathologic concept of angiogenesis and arteriogenesis.
World Neurosurg. 75:204–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yancopoulos GD, Davis S, Gale NW, et al:
Vascular-specific growth factors and blood vessel formation.
Nature. 407:242–248. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carmeliet P: Mechanisms of angiogenesis
and arteriogenesis. Nat Med. 6:389–395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng H, Dvorak HF and Mukhopadhyay D:
Vascular permeability factor (VPF)/vascular endothelial growth
factor (VEGF) receptor-1 downmodulates VPF/VEGF receptor-2-mediated
endothelial cell proliferation, but not migration, through
phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem.
276:26969–26979. 2001. View Article : Google Scholar
|
|
21
|
Roberts DM, Kearney JB, Johnson JH, et al:
The vascular endothelial growth factor (VEGF) receptor Flt-1
(VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel
formation. Am J Pathol. 164:1531–1535. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshimoto T, Houkin K, Takahashi A and Abe
H: Angiogenic factors in moyamoya disease. Stroke. 27:2160–2165.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Olfert IM, Howlett RA, Wagner PD and Breen
EC: Myocyte vascular endothelial growth factor is required for
exercise-induced skeletal muscle angiogenesis. Am J Physiol Regul
Integr Comp Physiol. 299:R1059–R1067. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lloyd PG, Prior BM, Li H, Yang HT and
Terjung RL: VEGF receptor antagonism blocks arteriogenesis, but
only partially inhibits angiogenesis, in skeletal muscle of
exercise-trained rats. Am J Physiol Heart Circ Physiol.
288:H759–H768. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kendall RL and Thomas KA: Inhibition of
vascular endothelial cell growth factor activity by an endogenously
encoded soluble receptor. Proc Natl Acad Sci USA. 90:10705–10709.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jacobi J, Tam BY, Wu G, et al: Adenoviral
gene transfer with soluble vascular endothelial growth factor
receptors impairs angiogenesis and perfusion in a murine model of
hindlimb ischemia. Circulation. 110:2424–2429. 2004. View Article : Google Scholar
|
|
27
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar
|
|
28
|
Ito TK, Ishii G, Saito S, et al:
Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access
to endothelial cells. Blood. 113:2363–2369. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ebos JM, Bocci G, Man S, et al: A
naturally occurring soluble form of vascular endothelial growth
factor receptor 2 detected in mouse and human plasma. Mol Cancer
Res. 2:315–326. 2004.PubMed/NCBI
|
|
30
|
Lorquet S, Berndt S, Blacher S, et al:
Soluble forms of VEGF receptor-1 and -2 promote vascular maturation
via mural cell recruitment. FASEB J. 24:3782–3795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu X, Zhang D, Shuo W, et al: Long term
outcome after conservative and surgical treatment of haemorrhagic
moyamoya disease. J Neurol Neurosurg Psychiatry. 84:258–265. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dixelius J, Cross MJ, Matsumoto T and
Claesson-Welsh L: Endostatin action and intracellular signaling:
beta-catenin as a potential target? Cancer Lett. 196:1–12. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lawler PR and Lawler J: Molecular basis
for the regulation of angiogenesis by thrombospondin-1 and -2. Cold
Spring Harb Perspect Med. 2:a0066272012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zacharek A, Chen J, Cui X, et al:
Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies
angiogenesis and vascular stabilization after stroke. J Cereb Blood
Flow Met. 27:1684–1691. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hanahan D: Signaling vascular
morphogenesis and maintenance. Science. 277:48–50. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Holash J, Wiegand SJ and Yancopoulos GD:
New model of tumor angiogenesis: dynamic balance between vessel
regression and growth mediated by angiopoietins and VEGF. Oncogene.
18:5356–5362. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nakamura M, Imai H, Konno K, et al:
Experimental investigation of encephalomyosynangiosis using
gyrencephalic brain of the miniature pig: histopathological
evaluation of dynamic reconstruction of vessels for functional
anastomosis. J Neurosurg Pediatr. 3:488–495. 2009. View Article : Google Scholar
|
